Polycythemia Vera Thrombosis Risk
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
The Polycythemia Vera Thrombosis Risk calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include age. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
ELN/Tefferi risk stratification for thrombosis in polycythemia vera: high risk if age >= 60 or prior thrombosis.
Clinical Indication
The Polycythemia Vera Thrombosis Risk is indicated for bedside clinical practice to support ELN/Tefferi risk stratification for thrombosis in polycythemia vera: high risk if age >= 60 or prior thrombosis.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: High-risk PV: cytoreductive therapy (hydroxyurea) plus low-dose aspirin recommended.
High risk = age >= 60 years OR history of thrombosis
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Age in years(years) |
| prior_thrombosis | boolean | Yes | History of arterial or venous thrombosis |
Evidence-Based References (EBM)
- Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599-1613.